401 related articles for article (PubMed ID: 17703603)
1. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
Martelli AM; Cocco L; Capitani S; Miscia S; Papa S; Manzoli FA
Eur J Histochem; 2007; 51 Suppl 1():125-31. PubMed ID: 17703603
[TBL] [Abstract][Full Text] [Related]
2. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?
Martelli AM; Faenza I; Billi AM; Manzoli L; Evangelisti C; Falà F; Cocco L
Cell Signal; 2006 Aug; 18(8):1101-7. PubMed ID: 16516442
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
4. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
6. Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN.
Mandl A; Sarkes D; Carricaburu V; Jung V; Rameh L
Mol Cell Biol; 2007 Dec; 27(23):8098-112. PubMed ID: 17893321
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Ptdlns(3,4,5)P3 signaling: an ongoing story.
Déléris P; Gayral S; Breton-Douillon M
J Cell Biochem; 2006 Jun; 98(3):469-85. PubMed ID: 16645993
[TBL] [Abstract][Full Text] [Related]
8. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
9. Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway.
Jethwa N; Chung GH; Lete MG; Alonso A; Byrne RD; Calleja V; Larijani B
J Cell Sci; 2015 Sep; 128(18):3456-65. PubMed ID: 26240177
[TBL] [Abstract][Full Text] [Related]
10. Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells.
Martelli AM; Evangelist C; Billi AM; Manzoli L; Papa V; Cocco L
Acta Biomed; 2007; 78 Suppl 1():113-9. PubMed ID: 17465329
[TBL] [Abstract][Full Text] [Related]
11. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system.
Neri LM; Borgatti P; Capitani S; Martelli AM
Biochim Biophys Acta; 2002 Oct; 1584(2-3):73-80. PubMed ID: 12385889
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
13. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.
Denning G; Jean-Joseph B; Prince C; Durden DL; Vogt PK
Oncogene; 2007 Jun; 26(27):3930-40. PubMed ID: 17213812
[TBL] [Abstract][Full Text] [Related]
14. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
15. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases.
Eramo MJ; Mitchell CA
Biochem Soc Trans; 2016 Feb; 44(1):240-52. PubMed ID: 26862211
[TBL] [Abstract][Full Text] [Related]
16. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
17. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
18. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression.
Lindsay Y; McCoull D; Davidson L; Leslie NR; Fairservice A; Gray A; Lucocq J; Downes CP
J Cell Sci; 2006 Dec; 119(Pt 24):5160-8. PubMed ID: 17158918
[TBL] [Abstract][Full Text] [Related]
19. PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt.
Seminario MC; Precht P; Bunnell SC; Warren SE; Morris CM; Taub D; Wange RL
Eur J Immunol; 2004 Nov; 34(11):3165-75. PubMed ID: 15468057
[TBL] [Abstract][Full Text] [Related]
20. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
